The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Becton Dickinson reported on Thursday that its fiscal fourth quarter revenues declined nearly 2 percent year over year while its base revenue grew approximately 4 percent.

The US Food and Drug Administration this week granted Emergency Use Authorization for Nanobiosym Precision Testing Services' Nano Test for COVID-19.

The US Food and Drug Administration last week granted Emergency Use Authorization for Rize Laboratory's SARS nCoV-2019 Multiplexed Assay.

Italian diagnostics firm DiaSorin said on Wednesday that it has received 510(k) clearance from the US Food and Drug Administration for its Simplexa Congenital CMV Direct kit for the detection of cytomegalovirus (CMV) DNA.

Wondfo (300482.SZ) released its third quarter report for 2022. The company's revenue in the first three quarters was CNY 4.696 billion, up 87.32% year-on-year; net profit attributable to the mother company was CNY 1.240 billion

PerkinElmer reported Tuesday its fiscal third quarter revenues dropped 17 percent year over year on declines in its COVID-19 business and pandemic-related lockdowns in China that dragged down the firm's diagnostics revenue.

Orders for Pacific Biosciences' new Revio long-read sequencing instrument are already rolling in, just a few weeks after its reveal, the company said this week as it announced a year-over-year decrease in third quarter revenues.

In the first three quarters of 2022, the company achieved revenue of CNY 1.18 billion, an increase of 39.32% year-on-year; net profit of CNY 308 million, an increase of 22.42% year-on-year; net profit of CNY 306 million, an increase of 28.84% year-on-year.

Qiagen reported double-digit year-over-year sales growth in its core non-COVID-related product portfolio on Monday afternoon, prompting the company to raise its full-year guidance.

Cepheid said Monday it secured CE-IVD marking for its group B Streptococcus assay, Xpert Xpress GBS, and will start selling the test in Europe this month.